Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC

Toni K. Choueiri, MD
Published: Friday, Feb 03, 2017



Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantinib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.

The response rate was different, favoring cabozantinib (46%) versus sunitinib (18%), explains Choueiri. Cabozantinib also had more effective tumor shrinkage but had the same adverse events as sunitinib.

The preliminary overall survival was looked at, even though it was not yet statistically significant, which seemed to favor cabozantinib. Overall, this randomized trial seems to show that cabozantinib is superior to sunitinib, says Choueiri.
 


Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantinib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.

The response rate was different, favoring cabozantinib (46%) versus sunitinib (18%), explains Choueiri. Cabozantinib also had more effective tumor shrinkage but had the same adverse events as sunitinib.

The preliminary overall survival was looked at, even though it was not yet statistically significant, which seemed to favor cabozantinib. Overall, this randomized trial seems to show that cabozantinib is superior to sunitinib, says Choueiri.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x